Corrigendum: Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1

Front Oncol. 2023 Apr 13:13:1163510. doi: 10.3389/fonc.2023.1163510. eCollection 2023.

Johnny Donovan¹, Zicheng Deng^{1

2

3}, Fenghua Bian¹, Samriddhi Shukla¹, Jose Gomez-Arroyo^{1

4}, Donglu Shi², Vladimir V Kalinichenko^{1

3}, Tanya V Kalin¹

¹ Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
² The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.
³ Center for Lung Regenerative Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
⁴ Division of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.

Abstract

[This corrects the article DOI: 10.3389/fonc.2023.1112859.].

Keywords: FOXM1 inhibitor; animal models; combination therapy; nanoparticles; rhabdomyosarcoma.